Showing 4381-4390 of 5627 results for "".
- Schwind Receives “SME Innovation Award“ in Germanyhttps://modernod.com/news/schwind-receives-sme-innovation-award-in-germany/2479288/Schwind eye-tech-solutions is one of the most innovative small and medium sized enterprises (SMEs) 2021/2022, according to a survey conducted by the independent Deutsche Gesellschaft für Verbraucherstudien (DtGV) in
- Randy Jackson, Patient Advocates to Share Stories of Managing Eye Health While Thriving With Diabetes During Live Virtual Eventhttps://modernod.com/news/randy-jackson-patient-advocates-to-share-stories-of-managing-eye-health-while-thriving-with-diabetes-during-live-virtual-event/2479286/“Focus on Diabetes,” a multi-year eye health initiative with the American Diabetes Association (ADA), VSP Vision Care, and Regeneron, will host a virtual live event, “The Real Stories Behind our Vision,” featuring Grammy-winning musician, producer Randy Jackson. Mr.
- Iveric Bio to Host Investor Symposium on Dry AMDhttps://modernod.com/news/iveric-bio-to-host-investor-symposium-on-dry-amd/2479282/Iveric bio announced details for its Dry Age-Related Macular Degeneration Virtual Symposium for investors and analysts being held on Friday, June 18, 2021 from 10 am to 12 pm Eastern Time. The symposium will include presentations on the company’s Zimura (avacincaptad pegol) pivotal program in geo
- Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics to Target Ophthalmic Diseaseshttps://modernod.com/news/oyster-point-pharma-announces-collaboration-with-adaptive-phage-therapeutics-to-target-ophthalmic-diseases/2479281/Oyster Point Pharma announced a newly formed research collaboration with Adaptive Phage Therapeutics (APT) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. APT’s PhageBank technology is engi
- Outlook Therapeutics Completes Patient Dosing in Phase 3 NORSE TWO Trial for Wet AMDhttps://modernod.com/news/outlook-therapeutics-completes-patient-dosing-in-phase-3-norse-two-trial-for-wet-amd/2479279/Outlook Therapeutics reported that it has administered the final dose to the last patient enrolled in its pivotal NORSE TWO safety and efficacy study evaluating ONS-5010 (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). Topline data are expected to be reported for NO
- EyeYon Medical Receives CE Mark for its EndoArt Implant to Treat Chronic Corneal Edemahttps://modernod.com/news/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema/2479277/EyeYon Medical announced that it has received CE Mark for its EndoArt after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. EyeYon says the EndoArt is the world’s first and only synthetic implant that replaces the human endothelium that the human
- Oxular Appoints Dr. Friedrich Asmus as Chief Medical Officerhttps://modernod.com/news/oxular-appoints-dr-friedrich-asmus-as-chief-medical-officer/2479267/Oxular Limited announced it has appointed Friedrich (Fritz) Asmus, MD, as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the company’s lead asset, OXU‑001, for the treatment of diabetic macular edema (DME), and to accelerate the development o
- High Caffeine Consumption May Be Associated With Increased Risk of Glaucomahttps://modernod.com/news/high-caffeine-consumption-may-be-associated-with-increased-risk-of-blinding-eye-disease/2479268/Consuming large amounts of daily caffeine may increase the risk of glaucoma more than three-fold for those with a genetic predisposition to higher eye pressure, according to an international multicenter study. The research led by the Icahn School of Medicine at Mount Sinai is the first to demonst
- Lighthouse Guild Starts Construction on New Technology Centerhttps://modernod.com/news/lighthouse-guild-starts-construction-on-new-technology-center/2479265/Lighthouse Guild has started construction on a Technology Center that will be the largest, premier assistive technology resource in the United States, according to a news release. Designed for people who are visually impaired and for all people who are using technology in order to help them, it i
- Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosahttps://modernod.com/news/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/2479261/Nanoscope Therapeutics announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through 1 year following a single intravitreal injection in a phase 1/2a clinical study with MCO. “We expect to begin the first randomized, placebo-contro